ArticleFrontiers in immunology2025
Rotavirus-specific neutralization assay enables evaluation of mucosal immune responses.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal infections are a major global health concern in humans and animals. Neutralization assays are considered the gold standard for evaluating functional antibodies but are typically limited to serum analysis. This often excludes mucosal sample types such as saliva or intestinal mucus, which may better reflect local immunity, particularly for enteric pathogens such as Rotaviruses (RV). We optimized and standardized a virus neutralization assay (VNA) for RVA to evaluate its applicability across serum, intestinal mucus, and saliva samples. Five key protocol variables were systematically assessed: (i) the applied trypsin concentration, (ii) the incubation time for proteolytic activation of the RV, (iii) the infection dose applied, (iv) the duration of neutralization time and (v) sample-specific factors that affect assay performance. The following parameters have proven to be optimal: (i) end concentration of 20 µg/ml Trypsin (ii) two hours for proteolytic activation of the RV, (iii) MOI of 0.5 - 3.0 x 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.